NRx Pharmaceuticals, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Wilmington DE US

Primary Industry

Pharmaceuticals

About

Founded in 2015 and based in Delaware, US, NeuroRx, Inc. is a clinical-stage pharmaceutical medicine that operates as a developer of an oral therapeutic treatment intended to treat mental health disorders. The company was co-founded by Daniel Javitt, Jonathan C. Javitt, Jonathan C. Javitt, RICHARD C. SIEGEL, and Robert Besthof. In August 2024, NRx Pharmaceuticals, Inc. raised USD 16 million in venture debt funding from various investors. The company trades on the Nasdaq under the ticker symbol NRXP. The firm develops and offers treatments for central nervous system disorders and pulmonary diseases. The company's lead investigational product, NRX-101, is designed for treating suicidal bipolar depression. Additionally, NRx is developing ZYESAMI (Aviptadil), aimed at addressing COVID-related respiratory failure. The firm is also engaged in expanding its offerings through the potential acquisition of interventional psychiatry clinics. The company intends to use the August 2024 funding to pay off current debt and to fund the filing of its two key drugs, NRX-100 and NRX-101, in the 2024 New Drug Application.

Current Investors

Streeterville Capital, LLC, Kinled Holding

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Mental Health Services, Pharmaceutical Research & Development

Website

www.nrxpharma.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.